Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | BRD2 | P25440 | 2/20 | 0.40 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.37 |
| ▸ | KAT7 | O95251 | 4/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.36 |
| ▸ | KAT6B | Q8WYB5 | 3/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 2/20 | 0.36 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28507830 | 0.82 | KAT7 (0.33) | BRD4BRD2BRD3MAPTMEN1 | |
| SCHEMBL29652540 | 0.82 | KAT7 (0.33) | BRD4BRD2BRD3MAPTMEN1 | |
| SCHEMBL31605639 | 0.81 | KAT6A (0.53) | ALPLKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL21596868 | 0.81 | KAT6A (0.53) | ALPLKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL21660434 | 0.78 | MAPT (0.43) | BRD4BRD2BRD3MAPTMEN1 | |
| SCHEMBL24429773 | 0.78 | KAT7 (0.41) | BRD4BRD2BRD3MAPTTP53 | |
| SCHEMBL21596880 | 0.77 | KAT6A (0.51) | ALPLKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL31605556 | 0.77 | KAT6A (0.51) | ALPLKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL29652415 | 0.72 | KAT7 (0.37) | BRD4BRD2BRD3MAPTMEN1 | |
| SCHEMBL24429772 | 0.72 | KAT6A (0.39) | MAPTMEN1KMT2ATP53ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220153710-A1 | Compounds | CTXT PTY LTD (AU) | 2022-05-19 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153710-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | BRD4 1909/4885BRD2 3332/4885BRD3 3519/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | BRD4 1913/4885BRD2 3343/4885BRD3 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.